BSE · 544220
Clinitech Laboratory Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹8 Cr with net profit ₹0 Cr — a 4.66% net margin, versus 5.76% the period before.
Shareholding
As of 2026-03-31
- Promoter64.2%
- Public35.48%
- FII0.32%
297 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #1 of 79 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,28,472 Cr | 242.67 | 13.55 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,08,166 Cr | 315.74 | 10.07 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,876 Cr | 270.47 | 7.26 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,315 Cr | 187.89 | 9.34 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,227 Cr | 299.63 | 9.23 | 8.48% | 8.36% |
| Global Health Limited | ₹38,526 Cr | 267.33 | 9.72 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹33,517 Cr | 135.03 | 8.94 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹31,558 Cr | 239.5 | 12.58 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹17,015 Cr | 256.67 | 5.47 | 10.37% | 17.18% |
| Dr. Agarwal's Health Care Limited | ₹15,494 Cr | 391.04 | 7.65 | 6.58% | 6.4% |
| Clinitech Laboratory Limited(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashClinitech Laboratory Limited reported revenue of Rs 8.46 Cr in the most recent fiscal year (Mar 2025). The company's debt-to-equity ratio stands at 0.07. Promoter shareholding as of March 31, 2026, is 64.20%, with no shares pledged.
Positives
- +The company's debt-to-equity ratio of 0.07 is low, indicating minimal reliance on debt.
- +Promoter holding of 64.20% as of March 31, 2026, represents a significant stake.
- +There are no promoter shares pledged, as indicated by 0% promoter pledge on March 31, 2026.
Negatives
- −Net profit in March 2025 was Rs 0.39 Cr, which is a marginal increase from Rs 0.37 Cr in March 2024.
- −Earnings per share (EPS) decreased to Rs 1.90 in March 2025 from Rs 2.37 in March 2024.
- −Promoter shareholding has decreased from 83.63% in January 2024 to 64.20% in March 2026.
- −The data does not provide any quarterly results since the last available annual filing in March 2025.
Financial performance
Clinitech Laboratory Limited's revenue increased to Rs 8.46 Cr in March 2025 from Rs 6.43 Cr in March 2024. Net profit for the same period was Rs 0.39 Cr in March 2025, an increase from Rs 0.37 Cr in March 2024. Earnings per share (EPS) were Rs 1.90 in March 2025, down from Rs 2.37 in March 2024.
Balance sheet
The company's debt-to-equity ratio is 0.07, indicating a low reliance on debt financing. Specific details regarding overall assets, liabilities, and other balance sheet components are not available in the provided data.
Ownership & pledges
As of March 31, 2026, promoters held 64.20% of the company's shares. Public shareholding was 35.48%, while FIIs held 0.32%. There were no promoter shares pledged as of March 31, 2026. The number of shareholders was 297 on March 31, 2026.
Regulatory & surveillance
No information regarding any surveillance measures or specific regulatory actions pertaining to Clinitech Laboratory Limited has been provided in the available data.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Clinitech Laboratory Limitedshare price & fundamentals